IRWD Ironwood Pharmaceuticals Inc.

9.03
+0.33  (+4%)
Previous Close 8.7
Open 8.76
Price To Book -6.45
Market Cap 1,413,155,033
Shares 156,495,574
Volume 811,071
Short Ratio
Av. Daily Volume 2,138,303
Stock charts supplied by TradingView

NewsSee all news

  1. Ironwood Pharmaceuticals and AstraZeneca Amend LINZESS® (linaclotide) Collaboration in China

    – Ironwood to receive up to $125 million, consisting of $35 million in non-contingent payments and up to $90 million in commercial milestones, in addition to tiered royalties up to 20 percent – – AstraZeneca obtains

  2. Ironwood Pharmaceuticals to Present at Upcoming September Investor Conferences

    Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) will present corporate updates at two upcoming investor conferences in September: 2019 Wells Fargo Healthcare Conference on Wednesday, September 4, 2019 at 2:25 p.m. ET at

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Approval announced August 21, 2017.
DUZALLO (LESINURAD AND ALLOPURINOL)
Hyperuricemia associated with gout
sNDA approval announced January 26, 2017.
Linaclotide 72 mcg dose for use in the treatment of adults
Chronic idiopathic constipation (CIC)
Phase 3b data met all endpoints - June 18, 2019.
Linaclotide
Irritable Bowel Syndrome with Constipation (IBS-C)
Phase 2a data released April 2016. Development to be discontinued due to disappointing data
IW-9179
Gastroparesis
Phase 3 data due 2H 2020.
IW-3718
Gastroesophageal reflux disease (GERD)
No additional trials planned.
IW-1701
Achalasia
Phase 2 top-line data due 2H 2020.
MD-7246
Irritable Bowel Syndrome

Latest News

  1. Ironwood Pharmaceuticals and AstraZeneca Amend LINZESS® (linaclotide) Collaboration in China

    – Ironwood to receive up to $125 million, consisting of $35 million in non-contingent payments and up to $90 million in commercial milestones, in addition to tiered royalties up to 20 percent – – AstraZeneca obtains

  2. Ironwood Pharmaceuticals to Present at Upcoming September Investor Conferences

    Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) will present corporate updates at two upcoming investor conferences in September: 2019 Wells Fargo Healthcare Conference on Wednesday, September 4, 2019 at 2:25 p.m. ET at